Efficacy of tenofovir alafenamide- or tenofovir disoproxil fumarate-containing regimens in adults with treatment-naïve HIV-hepatitis B co-infection
- 18 June 2025
- journal article
- Published by SAGE Publications in International Journal of STD & AIDS
Abstract
Background: Hepatitis B (HBV) infection affects 4%–14% of people with HIV infection in Turkey. Tenofovir alafenamide (TAF) is highly effective in treatment of HIV infection. While it is active against HBV, data on the use in HIV-HBV co-infection are limited. Patients and Methods: We analyzed the efficacy of tenofovir disoproxil fumarate (TDF)- and TAF-containing regimens in patients with HIV-HBV co-infection from six centers in Istanbul, Turkey. The results of the cohort of 36 months were presented. Results: 259 patients were enrolled: 146 and 113 were receiving TAF- and TDF-containing regimens respectively. Baseline characteristics were comparable except TAF-containing group was older; had higher CD4 cell count and lower rate of CD4 count ≤200 cells/μL. Baseline HIV-RNA were 8.2 log copies/mL and 6.8 log in TAF- and TDF-containing groups, respectively ( p = .059) and HBV-DNA levels were 8.1 log IU/mL in both groups. Thirty-eight and 39% of the patients were HBeAg-positive. After 36 months, undetectable HBV-DNA was noted in 88% and 87%, and undetectable HIV-RNA in 85% and in 83% of TAF and TDF-containing groups, respectively. The increase in mean CD4 cell was significant in both groups: Δ = 311 cells/μL in TAF- and Δ = 393 cells/μL in TDF-containing groups. Rates of HBeAg loss (63% vs 57%), HBeAg seroconversion (35% vs 29%), HBsAg loss (29% vs 27%), and HBsAg seroconversion (23% vs 16%) were comparable at 36 months of therapy. Conclusion: This real-life study showed that both TAF- and TDF-containing regimens are effective in co-infected patients. The rates of HBsAg loss seemed higher than those in HBV-monoinfected patients.Keywords
This publication has 18 references indexed in Scilit:
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trialThe Lancet HIV, 2023
- Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current dataAlimentary Pharmacology & Therapeutics, 2022
- Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction—A Prospective Cohort StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2020
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyThe Lancet Gastroenterology & Hepatology, 2020
- Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarateAIDS, 2019
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP studyClinical Microbiology and Infection, 2015
- Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIVThe Journal of Infectious Diseases, 2012
- Five‐year on‐treatment efficacy of lamivudine‐, tenofovir‐ and tenofovir + emtricitabine‐based HAART in HBV–HIV‐coinfected patientsJournal of Viral Hepatitis, 2012
- Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis BNew England Journal of Medicine, 2008